Picard Medical and SynCardia featured in Mullings Group interview series
Picard Medical (NYSE American: PMI), parent company of SynCardia Systems, has appeared in a two-part video interview series produced by The Mullings Group, a MedTech-focused executive search and media firm. The series features Picard Medical chief executive Patrick N.J. Schnegelsberg discussing the clinical role of total artificial heart therapy and the company's longer-term development strategy.
The SynCardia Total Artificial Heart is currently the only commercially available total artificial heart approved by the US FDA and Health Canada. The device replaces the native heart's pumping function entirely and is used as a bridge to transplant in patients with end-stage biventricular failure — a subset of advanced heart failure for whom left ventricular assist devices (LVADs) are insufficient. SynCardia says more than 2,100 implants have been performed across 27 countries, giving it a material base of real-world evidence relative to any competing platform in development.
The Emperor platform
Schnegelsberg used the interviews to highlight the Emperor Total Artificial Heart, the company's next-generation fully implantable system. Unlike the current SynCardia device, which requires an external driver, the Emperor platform is designed for full implantability — an important distinction for patient quality of life and mobility. The company did not disclose a regulatory timeline or clinical trial readout date for Emperor in the accompanying release, and the forward-looking statements disclaimer attached to the announcement signals that development risks remain material.
"For patients with end-stage biventricular failure, total artificial heart therapy is often the only viable option," Schnegelsberg said. "We are delivering that solution today, while advancing a fully implantable platform designed to expand access and redefine long-term mechanical heart replacement."
Market context
The advanced heart failure device market is undergoing a gradual shift. LVADs — led by Abbott's HeartMate 3 — dominate the mechanical circulatory support landscape for single-ventricle failure, but total artificial heart technology addresses a distinct and underserved patient cohort where biventricular support is required. The gap between organ donor supply and the number of patients awaiting heart transplantation continues to widen in both the US and Europe, which underpins the structural demand case for durable mechanical alternatives.
Several academic and commercial groups are pursuing next-generation total artificial heart designs, including fully implantable and miniaturised systems, though none has yet reached commercial approval in either the US or European markets. Picard Medical's regulatory head start with the SynCardia device is a meaningful competitive asset, provided the company can translate that clinical heritage into the Emperor programme's development pathway.
The interview series itself was filmed and produced by Dragonfly, a media subsidiary of The Mullings Group, and is available via YouTube. As with the RedChip-style IR media model, readers should note that featured placement in such series is typically a promotional activity rather than independent editorial coverage.